Inceptive
AI-native platform designing RNA molecules ("biological software") with deep learning
Biotech
📍 Palo Alto, CA
Founded 2021
Current Valuation
Private
PRIVATE
Inceptive is a Palo Alto AI-native biotech founded in 2021 by Jakob Uszkoreit, a co-inventor of the Transformer architecture and former Google Brain researcher. It uses deep learning to design novel RNA molecules — what it calls "biological software" — spanning mRNA, siRNA, ASOs and peptides, and partners with drugmakers to customize molecule-design models. It raised a ~$100M round in September 2023 led by Andreessen Horowitz and NVIDIA NVentures, and in 2026 signed a strategic AI collaboration with Alnylam Pharmaceuticals valued at up to ~$2B.
Company Profile
Growth
Platform/partnership stage; monetizing via large pharma collaborations
Last Round
Series A — $100M (Sep 2023) · Lead: Andreessen Horowitz / NVIDIA NVentures
Fundraising Status
Series A · $100M · 2y 10mo ago
privateTotal raised $100M2 disclosed rounds
Funding History
| Round | Amount | Date | Lead Investor | Post-Money |
|---|
| Series A | $100M | Sep 2023 | Andreessen Horowitz / NVIDIA NVentures | — |
| Seed | — | Jan 2021 | Andreessen Horowitz | — |
Founders & Key People
Jakob Uszkoreit
Investors
Andreessen Horowitz · NVIDIA NVentures
Products
- AI "biological software" platform for RNA design
- mRNA / siRNA / ASO / peptide sequence design
- In-vivo cell-therapy applications
Competitors
Atomic AI · Therna Biosciences · Moderna · Generate Biomedicines
BiotechRNA TherapeuticsGenerative AITechBioAI Drug Discovery
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.